GlaxoSmithKline News and Research

RSS

GSK will ensure experimental malaria vaccine is affordable, CEO says

GlaxoSmithKline CEO Andrew Witty said Wednesday the company would ensure that if an experimental malaria vaccine works, it would be priced reasonably, Reuters reports. "The vaccine, called Mosquirix [or RTS,S] and the first malaria shot to make it to final-stage trials, is creating a buzz ahead of a conference of 1,500 malaria experts in Nairobi next week," writes Reuters.

29 Oct 2009

Third-quarter fiscal 2009 results announced by Adolor

Adolor Corporation today reported a net loss of approximately $11.1 million, or ($0.24) per basic and diluted share, for the three months ended September 30, 2009 compared to a net loss of $13.3 million, or ($0.29) per basic and diluted share, for the three months ended September 30, 2008.

29 Oct 2009

Third-quarter 2009 financial results of Antigenics announced

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.

29 Oct 2009

Winning placement on Managed Care formularies, the first step for product's increased market share

In today's payer-driven pharmaceutical marketplace, winning placement on Managed Care formularies marks only the first step for a product's increased market share. However 90 percent of executives working in Managed Care rate pull through tactics, such as health fairs and formulary update letters, as effective ways to impact demand after formulary placement.

29 Oct 2009

Report on marketing the bio-pharmaceutical products released

The bio-pharmaceutical marketplace - and the Oncology therapeutic area in particular - continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that organizations with new Oncology products are scrutinizing their strategies and tactics to support market education.

29 Oct 2009

Third-quarter fiscal 2009 results announced by POZEN

POZEN Inc., today announced results for the third quarter ended September 30, 2009.

28 Oct 2009

Experts release policy recommendations to promote better medication adherence and health outcomes

A diverse group of health care and consumer organizations released five policy recommendations this week that are designed to promote better medication adherence and improved health outcomes for patients.

28 Oct 2009

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.

27 Oct 2009

SuperGen and GSK team up to discover and develop cancer therapeutics based on epigenetic targets

SuperGen, Inc. (NASDAQ:SUPG) and GlaxoSmithKline (NYSE:GSK) have entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets.

26 Oct 2009

GlaxoSmithKline's CERVARIX recommended by CDC for protection against cervical cancer

GlaxoSmithKline announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) recommended that CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic HPV 16 and 18.

22 Oct 2009

Weekly Digest releases report on investment opportunities in connection with the H1N1 outbreak

Weekly Digest (http://www.bullmarket.com/digest), a free investment research publication, announced the publication of a special report on investment opportunities in connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for GlaxoSmithKline, Sanofi-Aventis, Novartis, Baxter International, Roche Holding and several others.

21 Oct 2009

AFFiRiS reports encouraging results from clinical studies of its two Alzheimer's vaccines

AFFiRiS AG today announced that the primary endpoints have been met for the Phase I clinical studies of its two Alzheimer's vaccines AD01 and AD02, which demonstrated favourable safety and tolerability profiles. These results trigger a 10 million EUR milestone payment from licensee GlaxoSmithKline Biologicals.

21 Oct 2009

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

A cholera outbreak in Zimbabwe has infected more than 100, resulting in five deaths, state media said Tuesday, Reuters reports, "raising fears of a repeat of last year's epidemic that claimed more than 4,000 lives.

21 Oct 2009

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.

20 Oct 2009

GlaxoSmithKline to allow Apotex continue manufacturing their drug in Rwanda

GlaxoSmithKline Inc. (GSK) As part of its broad commitment to improving access to medicines and its ongoing support for Canada's Access to Medicines Regime (CAMR), GlaxoSmithKline confirms it will not object - through CAMR - to allow Canadian company (Apotex) to continue manufacturing their drug for the treatment of HIV/AIDS in Rwanda.

20 Oct 2009

Potential hazards of H1N1 vaccine and seasonal flu shot not disclosed, say protesters

As millions of Americans remain concerned about government-recommended flu shots, dozens of citizens dressed in full haz-mat suits will gather Wednesday, October 21, at the entrance to the Centers For Disease Control (CDC) to greet arriving members of the Advisory Committee on Immunization Practices.

20 Oct 2009

Fluarix seasonal influenza vaccine approved by the FDA

The U.S. Food and Drug Administration today approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Previously, this vaccine, which contains inactivated (killed) influenza A and B viruses, had been approved for use in adults, ages 18 years and older.

20 Oct 2009

GlaxoSmithKline may see increased sales of Relenza during the A/H1N1 2009 pandemic

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that during the A/H1N1 (swine flu) pandemic, GlaxoSmithKline could see its Relenza sales increase if Tamiflu-resistant strains of the virus spread. GlaxoSmithKline recently signed A/H1N1 2009 vaccine contracts with various governments for more than $3 billion and is donating supplies to less wealthy nations, ensuring that the company strikes a balance between profit and public health concerns.

20 Oct 2009

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).

20 Oct 2009

FDA approves new oral medication for renal cell carcinoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.

20 Oct 2009

GlaxoSmithKline News and Research

GSK will ensure experimental malaria vaccine is affordable, CEO says

Third-quarter fiscal 2009 results announced by Adolor

Third-quarter 2009 financial results of Antigenics announced

Winning placement on Managed Care formularies, the first step for product's increased market share

Report on marketing the bio-pharmaceutical products released

Third-quarter fiscal 2009 results announced by POZEN

Experts release policy recommendations to promote better medication adherence and health outcomes

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

SuperGen and GSK team up to discover and develop cancer therapeutics based on epigenetic targets

GlaxoSmithKline's CERVARIX recommended by CDC for protection against cervical cancer

Weekly Digest releases report on investment opportunities in connection with the H1N1 outbreak

AFFiRiS reports encouraging results from clinical studies of its two Alzheimer's vaccines

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

Tarsa Therapeutics receives license for Phase III oral calcitonin program

GlaxoSmithKline to allow Apotex continue manufacturing their drug in Rwanda

Potential hazards of H1N1 vaccine and seasonal flu shot not disclosed, say protesters

Fluarix seasonal influenza vaccine approved by the FDA

GlaxoSmithKline may see increased sales of Relenza during the A/H1N1 2009 pandemic

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

FDA approves new oral medication for renal cell carcinoma

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News